Floatz logo

1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Vancomycin
Cancer
M.D. Anderson Cancer CenterP2B (57)
Venetoclax
Cancer
AbbVieP3B (57)
Adebrelimab
Cancer
Hansoh BioMedical R&D CompanyP2B (56)
Catequentinib
Cancer
Lei LiP2/3B (56)
Decitabine
Cancer
Chinese PLA General HospitalP3B (56)
Enzalutamide
Cancer
ExelixisP3B (56)
Metformin
Cancer
PMV Pharmaceuticals, IncP3B (56)
Nepenthe
Cancer
M.D. Anderson Cancer CenterP3B (56)
Ondansetron
Cancer
Fate TherapeuticsP3B (56)
Romiplostim
Cancer
Ain Shams UniversityP3B (56)
S-1
Cancer
University of MalayaP2/3B (56)
Zanzalintinib
Cancer
ExelixisP3B (56)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1)
Cancer
Bristol-Myers SquibbP1/2CCC (55)
Abiraterone
Cancer
ExelixisP3CCC (55)
Antibody Drug Conjugate Composed Of A Humanized Monoclonal Antibody Targeting Cldn18.2 And Linker-Payload Mc-Vc-Pab-Mmae
Cancer
LaNova Australia Pty LimitedP1/2CCC (55)
Balstilimab
Cancer
Agenus Inc.P1/2CCC (55)
Foslinanib
Cancer
TaiRx, Inc.P2CCC (55)
Givastomig
Cancer
I-Mab Biopharma US LimitedP2CCC (55)
Meropenem
Cancer
M.D. Anderson Cancer CenterP2CCC (55)
Nab-Sirolimus
Cancer
Mirati Therapeutics Inc.P2CCC (55)
Olaparib
Cancer
Daewoong Pharmaceutical Co. LTD.P2CCC (55)
Panobinostat
Cancer
Asan Medical CenterP2CCC (55)
Pemigatinib
Cancer
Massachusetts General HospitalP2CCC (55)
Temsirolimus
Cancer
M.D. Anderson Cancer CenterP2CCC (55)
Tepotinib
Cancer
Institute of Cancer Research, United KingdomP2CCC (55)
Tinengotinib
Cancer
TransThera Sciences (Nanjing), Inc.P1/2CCC (55)
Vismodegib
Cancer
Helsinki University Central HospitalP2CCC (55)
Alnodesertib
Cancer
Artios Pharma LtdP2CCC (54)
Anti-Pd-L1 Monoclonal Antibody Shr-1316
Cancer
Shandong Suncadia Medicine Co., Ltd.P2CCC (54)
Bendamustine
Cancer
Fate TherapeuticsP2CCC (54)
Cilastatin
Cancer
M.D. Anderson Cancer CenterP2CCC (54)
Cobimetinib
Cancer
University Health Network, TorontoP2CCC (54)
Dasatinib
Cancer
Canadian Cancer Trials GroupP2CCC (54)
Entrectinib
Cancer
Cancer Research UKP2/3CCC (54)
Famitinib
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.P2CCC (54)
Fluzoparib
Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.P2CCC (54)
Gerpevir
Cancer
Children's Oncology GroupP3CCC (54)
gh21
Cancer
Suzhou Genhouse Bio Co., Ltd.P2CCC (54)
Gotistobart
Cancer
OncoC4, Inc.P3CCC (54)
Iscar Quercus
Cancer
University Hospital, Basel, SwitzerlandP4CCC (54)
Ponatinib
Cancer
University Health Network, TorontoP2CCC (54)
Shr-1826
Cancer
Shandong Suncadia Medicine Co., Ltd.P2CCC (54)
Shr-A2102
Cancer
Shandong Suncadia Medicine Co., Ltd.P2CCC (54)
Trastuzumab Deruxtecan
Cancer
Baptist Health South FloridaP2CCC (54)
Vemurafenib
Cancer
Seoul National University Bundang HospitalP2CCC (54)
Adebellizumab
Cancer
Zhejiang UniversityP2CCC (53)
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre
Cancer
Thomas Jefferson UniversityP2CCC (53)
Al18F-PSMA-BCH
Cancer
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP2CCC (53)
Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes
Cancer
M.D. Anderson Cancer CenterP2CCC (53)
Asca101
Cancer
MetaFinesP2CCC (53)
Showing 101 to 150 of 1,380 assets
PreviousPage 3 of 28Next